JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.